NIH Refines Genomic Data Sharing Online Tools
Published Date: 3/12/2026
Notice
Summary
The NIH wants your thoughts on updating their online forms that help share genomic data for research. This affects researchers who submit genetic info and aims to make the process smoother and clearer. You’ve got until April 13, 2026, to share your feedback—no extra costs, just a chance to improve how data gets shared!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Modernized Web Forms to Reduce Burden
The NIH is updating the dbGaP data registration/submission and Authorized Access online interfaces and adding a new NIH Submission Registration Information Form to modernize submissions. NIH says these updates are intended to reduce administrative burden and provide enhanced oversight for researchers who submit large-scale human and non-human genomic data for NIH-funded research.
Requirement to Submit Large-Scale Genomic Data
The NIH Genomic Data Sharing (GDS) Policy expects large-scale human and non-human genomic data generated with NIH funds to be submitted to an NIH-designated repository (such as dbGaP). As part of submission, the submitting institution must certify the data are appropriate to share and secondary users must submit a Data Access Request (DAR) to the NIH Data Access Committee for review and approval.
Estimated Time Burden: 9,784 Annual Hours
NIH requests OMB approval for 3 years and estimates the total annualized respondent burden across all forms and systems at 9,784 hours, with no costs to respondents other than their time. The current OMB expiration date shown is 03/31/2026.
Security and CADR Compliance Requirements
NIH updated dbGaP and the Authorized Access System to collect information about data security standards and to comply with national security directives and 'Required Security and Operational Standards for NIH Controlled-Access Data Repositories' (NIH CADR requirements). Some non-genomic NIH controlled-access data repositories have leveraged the dbGaP systems to meet those CADR standards.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2026-04787, Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Investor Form
The SEC is asking for comments to extend the use of its easy online Investor Form, which helps people send questions or complaints about investments. This form makes it simpler for about 13,000 investors a year to reach the SEC and helps the agency handle issues faster. Using the form is optional, and there’s no cost or deadline change, just a smooth way to keep things running well.
Next: 2026-04789, Agency Information Collection Activities; Endangered and Threatened Wildlife, Experimental Populations
The Fish and Wildlife Service is renewing three important info collections about endangered animals like gray wolves and grizzly bears, without making any changes. This affects people who work with or study these special animal groups and helps keep tracking smooth and easy. You’ve got until May 11, 2026, to share your thoughts, and there’s no new cost or paperwork hassle coming your way!